Effect of neoadjuvant chemoradiotherapy on p53 and SOX2 protein expression in esophageal adenocarcinoma

Lucia Suzuki, Daan Nieboer, Jan Jb van Lanschot, Manon Cw Spaander, Leendert Hj Looijenga, Katharina Biermann

Onderzoeksoutput: Bijdrage aan tijdschriftArtikelpeer review

Samenvatting

Aim: To determine if neoadjuvant chemoradiotherapy (nCRT) affects p53 and SOX2 expression in esophageal adenocarcinoma (EAC). Materials & methods: Comparison of p53 and SOX2 expression in 100 paired pre- and post-nCRT EAC samples. Results: Aberrant p53 was largely concordant (75/83, 90%), while 13/18 (72%) pre-nCRT samples with wild-type (WT) p53 staining, showed aberrant staining in paired post-nCRT samples. Similarly, 31/45 (69%) with previous WT SOX2 showed SOX2 loss in paired post-nCRT samples, whereas aberrant SOX2 loss was concordant in 50/55 (91%) cases. The prognostic values of both markers regarding survival differ before and after nCRT. Conclusion: Aberrant expression of p53 and SOX2 staining in EAC tissue is unaffected by nCRT. Conversely, the WT-staining pattern frequently changed to aberrant expression.

Originele taal-2Engels
Pagina's (van-tot)785-793
Aantal pagina's9
TijdschriftBiomarkers in medicine
Volume14
Nummer van het tijdschrift9
DOI's
StatusGepubliceerd - jun. 2020

Vingerafdruk

Duik in de onderzoeksthema's van 'Effect of neoadjuvant chemoradiotherapy on p53 and SOX2 protein expression in esophageal adenocarcinoma'. Samen vormen ze een unieke vingerafdruk.

Citeer dit